0	12	Purification	Purification	NNP
13	15	of	of	IN
16	21	TCF-1	tcf-1	NN
22	27	alpha	alpha	NN
27	28	,	,	,
29	30	a	a	DT
31	46	T-cell-specific	t-cell-specific	JJ
47	60	transcription	transcription	NN
61	67	factor	factor	NN
68	72	that	that	WDT
73	82	activates	activate	VBZ
83	86	the	the	DT
87	93	T-cell	t-cell	NN
94	102	receptor	receptor	NN
103	104	C	C	NNP
105	110	alpha	alpha	NN
111	115	gene	gene	NN
116	124	enhancer	enhancer	NN
125	127	in	in	IN
128	129	a	a	DT
130	147	context-dependent	context-dependent	JJ
148	154	manner	manner	NN
154	155	.	.	.

157	160	The	the	DT
161	176	differentiation	differentiation	NN
177	179	of	of	IN
180	181	T	t	NN
182	187	cells	cell	NNS
188	192	into	into	IN
193	205	functionally	functionally	RB
206	213	diverse	diverse	JJ
214	228	subpopulations	subpopulation	NNS
229	231	is	be	VBZ
232	242	controlled	control	VBN
243	245	in	in	IN
246	250	part	part	NN
250	251	,	,	,
252	254	by	by	IN
255	270	transcriptional	transcriptional	JJ
271	281	activation	activation	NN
282	285	and	and	CC
286	295	silencing	silencing	NN
295	296	;	;	:
297	304	however	however	RB
304	305	,	,	,
306	312	little	little	JJ
313	315	is	be	VBZ
316	321	known	know	VBN
322	324	in	in	IN
325	331	detail	detail	NN
332	337	about	about	IN
338	341	the	the	DT
342	350	proteins	protein	NNS
351	355	that	that	WDT
356	365	influence	influence	VBP
366	370	this	this	DT
371	384	developmental	developmental	JJ
385	392	process	process	NN
392	393	.	.	.

394	396	We	we	PRP
397	401	have	have	VBP
402	410	purified	purify	VBN
411	412	a	a	DT
413	416	new	new	JJ
417	432	T-cell-specific	t-cell-specific	JJ
433	439	factor	factor	NN
439	440	,	,	,
441	446	TCF-1	tcf-1	NN
447	452	alpha	alpha	NN
452	453	,	,	,
454	458	that	that	WDT
459	461	is	be	VBZ
462	472	implicated	implicate	VBN
473	475	in	in	IN
476	479	the	the	DT
480	490	activation	activation	NN
491	493	of	of	IN
494	499	genes	gene	NNS
500	508	encoding	encode	VBG
509	510	a	a	DT
511	516	major	major	JJ
517	526	component	component	NN
527	529	of	of	IN
530	533	the	the	DT
534	539	human	human	JJ
540	546	T-cell	t-cell	NN
547	555	receptor	receptor	NN
556	557	(	(	(
557	560	TCR	TCR	NNP
560	561	)	)	)
561	562	.	.	.

563	568	TCF-1	tcf-1	NN
569	574	alpha	alpha	NN
574	575	,	,	,
576	586	originally	originally	RB
587	597	identified	identify	VBN
598	601	and	and	CC
602	610	purified	purify	VBN
611	618	through	through	IN
619	622	its	its	PRP$
623	630	binding	bind	VBG
631	636	sites	site	NNS
637	639	on	on	IN
640	643	the	the	DT
644	649	HIV-1	HIV-1	NNP
650	658	promoter	promoter	NN
658	659	,	,	,
660	663	was	be	VBD
664	669	found	find	VBN
670	672	to	to	TO
673	677	bind	bind	VB
678	680	to	to	TO
681	684	the	the	DT
685	688	TCR	TCR	NNP
689	694	alpha	alpha	NN
695	703	enhancer	enhancer	NN
704	707	and	and	CC
708	710	to	to	TO
711	720	promoters	promoter	NNS
721	724	for	for	IN
725	732	several	several	JJ
733	738	genes	gene	NNS
739	748	expressed	express	VBN
749	751	at	at	IN
752	765	significantly	significantly	RB
766	773	earlier	early	JJR
774	780	stages	stage	NNS
781	783	of	of	IN
784	790	T-cell	t-cell	NN
791	802	development	development	NN
803	807	than	than	IN
808	811	the	the	DT
812	815	TCR	TCR	NNP
816	821	alpha	alpha	NN
822	826	gene	gene	NN
827	828	(	(	(
828	832	e.g.	e.g.	FW
832	833	,	,	,
834	840	p56lck	p56lck	NN
841	844	and	and	CC
845	848	CD3	cd3	NN
849	854	delta	delta	NN
854	855	)	)	)
855	856	.	.	.

857	866	Sequences	sequence	NNS
867	874	related	relate	VBN
875	877	to	to	TO
878	881	the	the	DT
882	887	TCF-1	tcf-1	NN
888	893	alpha	alpha	NN
894	901	binding	binding	NN
902	907	motif	motif	NN
908	909	(	(	(
909	926	5’-GGCACCCTTTGA-3	5'-GGCACCCTTTGA-3	NNP
926	927	’	'	''
927	928	)	)	)
929	932	are	be	VBP
933	937	also	also	RB
938	943	found	find	VBN
944	946	in	in	IN
947	950	the	the	DT
951	956	human	human	JJ
957	960	TCR	TCR	NNP
961	966	delta	delta	NN
967	968	(	(	(
968	971	and	and	CC
972	980	possibly	possibly	RB
981	984	TCR	TCR	NNP
985	989	beta	beta	NN
989	990	)	)	)
991	1000	enhancers	enhancer	NNS
1000	1001	.	.	.

1002	1014	Southwestern	Southwestern	NNP
1015	1018	and	and	CC
1019	1022	gel	gel	NN
1023	1035	renaturation	renaturation	NN
1036	1047	experiments	experiment	NNS
1048	1052	with	with	IN
1053	1056	the	the	DT
1057	1060	use	use	NN
1061	1063	of	of	IN
1064	1072	purified	purify	VBN
1073	1080	protein	protein	NN
1081	1090	fractions	fraction	NNS
1091	1099	revealed	reveal	VBD
1100	1104	that	that	IN
1105	1110	TCF-1	tcf-1	NN
1111	1116	alpha	alpha	NN
1117	1125	activity	activity	NN
1126	1128	is	be	VBZ
1129	1136	derived	derive	VBN
1137	1141	from	from	IN
1142	1143	a	a	DT
1144	1150	family	family	NN
1151	1153	of	of	IN
1154	1157	57-	57-	CD
1158	1160	to	to	TO
1161	1166	53-kD	53-kd	JJ
1167	1175	proteins	protein	NNS
1176	1180	that	that	WDT
1181	1184	are	be	VBP
1185	1195	abundantly	abundantly	RB
1196	1205	expressed	express	VBN
1206	1208	in	in	IN
1209	1215	mature	mature	JJ
1216	1219	and	and	CC
1220	1228	immature	immature	JJ
1229	1235	T-cell	t-cell	NN
1236	1241	lines	line	NNS
1242	1243	(	(	(
1243	1249	Jurkat	Jurkat	NNP
1249	1250	,	,	,
1251	1259	CCRF-CEM	CCRF-CEM	NNP
1259	1260	)	)	)
1261	1264	and	and	CC
1265	1268	not	not	RB
1269	1271	in	in	IN
1272	1278	mature	mature	JJ
1279	1280	B	B	NNP
1281	1286	cells	cell	NNS
1287	1288	(	(	(
1288	1290	JY	JY	NNP
1290	1291	,	,	,
1292	1299	Namalwa	Namalwa	NNP
1299	1300	)	)	)
1301	1303	or	or	CC
1304	1315	nonlymphoid	nonlymphoid	JJ
1316	1317	(	(	(
1317	1321	HeLa	HeLa	NNP
1321	1322	)	)	)
1323	1327	cell	cell	NN
1328	1333	lines	line	NNS
1333	1334	.	.	.

1335	1336	A	a	DT
1337	1342	small	small	JJ
1343	1348	95-bp	95-bp	JJ
1349	1357	fragment	fragment	NN
1358	1360	of	of	IN
1361	1364	the	the	DT
1365	1368	TCR	TCR	NNP
1369	1374	alpha	alpha	NN
1375	1382	control	control	NN
1383	1389	region	region	NN
1390	1394	that	that	WDT
1395	1403	contains	contain	VBZ
1404	1407	the	the	DT
1408	1413	TCF-1	tcf-1	NN
1414	1419	alpha	alpha	NN
1420	1427	binding	binding	NN
1428	1432	site	site	NN
1433	1443	juxtaposed	juxtapose	VBN
1444	1451	between	between	IN
1452	1453	a	a	DT
1454	1467	cAMP-response	camp-response	JJ
1468	1475	element	element	NN
1476	1477	(	(	(
1477	1480	the	the	DT
1481	1484	CRE	cre	NN
1485	1487	or	or	CC
1488	1489	T	t	NN
1490	1495	alpha	alpha	SYM
1496	1497	1	1	CD
1498	1503	motif	motif	NN
1503	1504	)	)	)
1505	1508	and	and	CC
1509	1512	the	the	DT
1513	1520	binding	bind	VBG
1521	1525	site	site	NN
1526	1529	for	for	IN
1530	1531	a	a	DT
1532	1540	distinct	distinct	JJ
1541	1558	lymphoid-specific	lymphoid-specific	JJ
1559	1566	protein	protein	NN
1567	1568	(	(	(
1568	1573	TCF-2	tcf-2	NN
1574	1579	alpha	alpha	NN
1579	1580	)	)	)
1581	1588	behaved	behave	VBD
1589	1591	as	as	IN
1592	1593	a	a	DT
1594	1600	potent	potent	JJ
1601	1616	T-cell-specific	t-cell-specific	JJ
1617	1625	enhancer	enhancer	NN
1626	1628	in	in	FW
1629	1633	vivo	vivo	FW
1633	1634	.	.	.

1635	1641	Tandem	tandem	JJ
1642	1648	copies	copy	NNS
1649	1651	of	of	IN
1652	1656	this	this	DT
1657	1665	enhancer	enhancer	NN
1666	1676	functioned	function	VBD
1677	1692	synergistically	synergistically	RB
1693	1695	in	in	IN
1696	1702	mature	mature	JJ
1703	1704	(	(	(
1704	1710	Jurkat	Jurkat	NNP
1710	1711	)	)	)
1712	1718	T-cell	t-cell	NN
1719	1724	lines	line	NNS
1725	1727	as	as	RB
1728	1732	well	well	RB
1733	1735	as	as	IN
1736	1743	resting	rest	VBG
1744	1747	and	and	CC
1748	1757	activated	activate	VBN
1758	1766	immature	immature	JJ
1767	1768	(	(	(
1768	1776	CCRF-CEM	CCRF-CEM	NNP
1776	1777	)	)	)
1778	1784	T-cell	t-cell	NN
1785	1790	lines	line	NNS
1790	1791	.	.	.

1792	1800	Mutation	mutation	NN
1801	1803	of	of	IN
1804	1807	the	the	DT
1808	1813	TCF-1	tcf-1	NN
1814	1819	alpha	alpha	NN
1820	1827	binding	binding	NN
1828	1832	site	site	NN
1833	1843	diminished	diminish	VBD
1844	1852	enhancer	enhancer	NN
1853	1861	activity	activity	NN
1862	1865	and	and	CC
1866	1875	disrupted	disrupt	VBD
1876	1879	the	the	DT
1880	1889	synergism	synergism	NN
1890	1898	observed	observe	VBN
1899	1901	in	in	FW
1902	1906	vivo	vivo	FW
1907	1914	between	between	IN
1915	1921	tandem	tandem	JJ
1922	1930	enhancer	enhancer	NN
1931	1938	repeats	repeat	NNS
1938	1939	.	.	.

1940	1943	The	the	DT
1944	1949	TCF-1	tcf-1	NN
1950	1955	alpha	alpha	NN
1956	1963	binding	binding	NN
1964	1968	site	site	NN
1969	1972	was	be	VBD
1973	1977	also	also	RB
1978	1986	required	require	VBN
1987	1990	for	for	IN
1991	1994	TCR	TCR	NNP
1995	2000	alpha	alpha	NN
2001	2009	enhancer	enhancer	NN
2010	2018	activity	activity	NN
2019	2021	in	in	IN
2022	2039	transcriptionally	transcriptionally	RB
2040	2046	active	active	JJ
2047	2055	extracts	extract	NNS
2056	2060	from	from	IN
2061	2067	Jurkat	Jurkat	NNP
2068	2071	but	but	CC
2072	2075	not	not	RB
2076	2080	HeLa	HeLa	NNP
2081	2086	cells	cell	NNS
2086	2087	,	,	,
2088	2098	confirming	confirm	VBG
2099	2103	that	that	IN
2104	2109	TCF-1	tcf-1	NN
2110	2115	alpha	alpha	NN
2116	2118	is	be	VBZ
2119	2120	a	a	DT
2121	2136	T-cell-specific	t-cell-specific	JJ
2137	2150	transcription	transcription	NN
2151	2157	factor	factor	NN
2157	2158	.	.	.

2159	2168	Curiously	curiously	RB
2168	2169	,	,	,
2170	2173	the	the	DT
2174	2179	TCF-1	tcf-1	NN
2180	2185	alpha	alpha	NN
2186	2193	binding	binding	NN
2194	2201	element	element	NN
2202	2205	was	be	VBD
2206	2214	inactive	inactive	JJ
2215	2217	in	in	FW
2218	2222	vivo	vivo	FW
2223	2227	when	when	WRB
2228	2235	removed	remove	VBN
2236	2240	from	from	IN
2241	2244	its	its	PRP$
2245	2256	neighboring	neighbor	VBG
2257	2265	elements	element	NNS
2266	2268	on	on	IN
2269	2272	the	the	DT
2273	2276	TCR	TCR	NNP
2277	2282	alpha	alpha	NN
2283	2291	enhancer	enhancer	NN
2292	2295	and	and	CC
2296	2306	positioned	position	VBN
2307	2309	in	in	IN
2310	2313	one	one	CD
2314	2316	or	or	CC
2317	2321	more	more	JJR
2322	2328	copies	copy	NNS
2329	2337	upstream	upstream	RB
2338	2340	of	of	IN
2341	2342	a	a	DT
2343	2355	heterologous	heterologous	JJ
2356	2364	promoter	promoter	NN
2364	2365	.	.	.

2366	2370	Thus	thus	RB
2370	2371	,	,	,
2372	2375	the	the	DT
2376	2391	transcriptional	transcriptional	JJ
2392	2400	activity	activity	NN
2401	2403	of	of	IN
2404	2409	TCF-1	tcf-1	NN
2410	2415	alpha	alpha	NN
2416	2423	appears	appear	VBZ
2424	2426	to	to	TO
2427	2433	depend	depend	VB
2434	2436	on	on	IN
2437	2440	the	the	DT
2441	2446	TCF-2	tcf-2	NN
2447	2452	alpha	alpha	NN
2453	2456	and	and	CC
2457	2458	T	t	NN
2459	2464	alpha	alpha	NN
2465	2466	1	1	CD
2467	2468	(	(	(
2468	2472	CREB	CREB	NNP
2472	2473	)	)	)
2474	2487	transcription	transcription	NN
2488	2495	factors	factor	NNS
2496	2499	and	and	CC
2500	2503	the	the	DT
2504	2511	context	context	NN
2512	2514	of	of	IN
2515	2518	its	its	PRP$
2519	2526	binding	bind	VBG
2527	2531	site	site	NN
2532	2538	within	within	IN
2539	2542	the	the	DT
2543	2546	TCR	TCR	NNP
2547	2552	alpha	alpha	NN
2553	2561	enhancer	enhancer	NN
2561	2562	.	.	.